Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET

Company Participants

Ryan Asay – Senior Vice President-Corporate Affairs
Mark Goldsmith – Chairman and Chief Executive Officer
Steve Kelsey – President-Research and Development
Jack Anders – Chief Financial Officer
Wei Lin – Chief Medical Officer

Conference Call Participants

Peter Lawson – Barclays
Michael Schmidt – Guggenheim Securities
Jay Olson – Oppenheimer
Marc Frahm – TD Cowen
Alec Stranahan – Bank of America
Jonathan Chang – Leerink Partners
Eric Joseph – J.P. Morgan
Laura Prendergast – Raymond James

Operator

Good day and thank you for standing by. Welcome to Revolution Medicine’s Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to hand the conference over to your first speaker today, Ryan Asay, Senior Vice President of Corporate Affairs. Please go ahead.

Ryan Asay

Thank you, and welcome, everyone, to the third quarter 2024 earnings call. Joining me on today’s call are Dr. Mark Goldsmith, Revolution Medicine’s Chairman and Chief Executive Officer; Dr. Steve Kelsey, our President of R&D; and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, will join us for the Q&A portion of today’s call.

I would like to inform you that certain statements we make during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly report on Form 10-Q that are filed with the U.S. Securities and Exchange Commission. This afternoon we released financial results for the quarter ended September 30, 2024 and recent corporate updates. The press release is available in the Investors section of our website at revmed.com.

With that, I’ll turn the call over to Dr. Mark Goldsmith, Revolution Medicines’ Chairman and Chief Executive Officer. Mark?

Mark Goldsmith

Thanks, Ryan. It’s good to be with you this afternoon. At Revolution Medicines, we are committed to revolutionizing treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative targeted medicines. We believe that we have increasingly been able to demonstrate that our portfolio of RAS(ON) inhibitors has the potential to provide meaningful impact for patients living with some of the most difficult to treat cancers.